Tags : Moderate-to-Severe

Pfizer and Eli Lilly Report Results of Tanezumab in P-III

Shots: The P-III OA study involves assessing of tanezumab (2.5mg/5mg, SC) vs PBO in 849 patients in the ratio (1:1:1) with moderate-to-severe OA pain of the knee or hip across EU and Japan for 24 wks. The study showed a meeting in all 1EPs improvement in pain, physical function with well-tolerated results and has shown […]Read More

Indivior Receives Health Canada Approval for Sublocade (SC) (Buprenorphine Extended-Release)

Shots: The approval of Sublocade(qmt) in combination with medication-assisted treatment (MAT) is indicated to treat OUD in adults, using Atrigel delivery system The clinical trials demonstrated, that Injection site reactions were reported in 16% of the patients. None of the injection site reactions were serious and one led to study treatment discontinuation Health Canada has […]Read More